Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian B Spear

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Current Opinion in Pharmacology|September 3, 2008
Pharmacogenetics: improving drug and dose selectionAnahita Bhathena, Brian B Spear
Veterinary Journal (London, England : 1997)|November 4, 2009
Theranostics in veterinary medicine: where are we heading?Eric A G Blomme, Brian B Spear
Pharmacogenetics|July 13, 2004
Prediction of successful weight reduction under sibutramine therapyLeonardo Sahelijo, David A Katz, Brian B Spear
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 15, 2007
Frequency of the frame-shifting CYP2D7 138delT polymorphism in a large, ethnically diverse sample populationAnahita Bhathena, Toby Mueller, David R Grimm, et al.
Hepatology (Baltimore, Md.)|December 25, 2004
Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacinMichael J Liguori, Mark G Anderson, Stanley Bukofzer, et al.
Pharmacogenetics|April 30, 2004
Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokineticsKatherine D Furman, David R Grimm, Toby Mueller, et al.
Pharmacogenomics|June 24, 2004
Pharmacogenomic data submissions to the FDA: clinical case studiesWilliam L Trepicchio, Grant A Williams, David Essayan, et al.
Bioethics|May 10, 2006
Returning genetic research results to individuals: points-to-considerGaile Renegar, Christopher J Webster, Steffen Stuerzebecher, et al.
Pharmacogenomics|December 15, 2010
Development and regulatory strategies for drug and diagnostic co-developmentLois M Hinman, Kevin M Carl, Brian B Spear, et al.
Clinical Pharmacology and Therapeutics|March 4, 2006
Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokineticsDavid A Katz, Robert Carr, David R Grimm, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Current Opinion in Pharmacology|September 3, 2008
Pharmacogenetics: improving drug and dose selectionAnahita Bhathena, Brian B Spear
Veterinary Journal (London, England : 1997)|November 4, 2009
Theranostics in veterinary medicine: where are we heading?Eric A G Blomme, Brian B Spear
Pharmacogenetics|July 13, 2004
Prediction of successful weight reduction under sibutramine therapyLeonardo Sahelijo, David A Katz, Brian B Spear
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 15, 2007
Frequency of the frame-shifting CYP2D7 138delT polymorphism in a large, ethnically diverse sample populationAnahita Bhathena, Toby Mueller, David R Grimm, et al.
Hepatology (Baltimore, Md.)|December 25, 2004
Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacinMichael J Liguori, Mark G Anderson, Stanley Bukofzer, et al.
Pharmacogenetics|April 30, 2004
Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokineticsKatherine D Furman, David R Grimm, Toby Mueller, et al.
Pharmacogenomics|June 24, 2004
Pharmacogenomic data submissions to the FDA: clinical case studiesWilliam L Trepicchio, Grant A Williams, David Essayan, et al.
Bioethics|May 10, 2006
Returning genetic research results to individuals: points-to-considerGaile Renegar, Christopher J Webster, Steffen Stuerzebecher, et al.
Pharmacogenomics|December 15, 2010
Development and regulatory strategies for drug and diagnostic co-developmentLois M Hinman, Kevin M Carl, Brian B Spear, et al.
Clinical Pharmacology and Therapeutics|March 4, 2006
Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokineticsDavid A Katz, Robert Carr, David R Grimm, et al.
Pageof 2